CD19 and B-cell non-Hodgkin lymphoma: scFv-engineered UCB-NK cells have entered four Phase I/II studies, two with anti-CD19 CAR-NK cells against B cell lymphoma (NCT03056339 and NCT03579927, Additional file 2: Table S2, rows 12–13), one with anti-CD5 CAR-NK against multiple hematological malignancies (NCT05110742, Additional file 2: Table S2, row 14), and one with anti-CD70 CAR (NCT05092451, Additional file 2: Table S2, row 15).